CTSO Stock UPDATES Cytosorbents Cor (CTSO) 0.2372 09/09/2014

Cytosorbents Cor (CTSO) 0.2372 $CTSO

CytoSorbents Announces U.S. Cardiac Surgery Advisory Board
PR Newswire - Tue Sep 09, 7:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a blood purification company using its CytoSorb® extracorporeal cytokine adsorber to prevent or treat organ failure in life-threatening conditions, announced its U.S. Cardiac Surgery Advisory Board (CSAB) that includes leaders in cardiothoracic surgery, surgical critical care, extracorporeal therapy, and inflammation. The Board will oversee the use of CytoSorb® in cardiac surgery trials in the United States and complement the Company's advisors abroad.

In Memoriam: Joseph Rubin (1938-2014) - CytoSorbents Co-founder and Board Director
PR Newswire - Fri Sep 05, 7:50AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company, remembers the significant contributions of its co-founder and Board Director, Joseph Rubin, Esq., who passed away on September 1, 2014 at age 76.

CytoSorbents to Present at the 2014 Rodman & Renshaw Annual Global Investment Conference
PR Newswire - Wed Sep 03, 8:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO) announced that Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present at the Rodman & Renshaw Annual Global Investment Conference (sponsored by H.C. Wainwright & Co) taking place on September 8-10th in New York City. CytoSorbents is a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber to treat patients with life-threatening inflammatory conditions in the intensive care unit in nineteen countries worldwide.

CytoSorbents Records Another Solid Quarter of Growth in Q2 2014
PR Newswire - Tue Aug 12, 3:05PM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber to treat critically-ill patients in multiple countries worldwide, reported second quarter financial and operational results for the three and six months ended June 30, 2014.

CytoSorbents to Report Q2 2014 Operating and Financial Results
PR Newswire - Wed Aug 06, 8:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood filter to treat life-threatening illnesses in the intensive care unit, will report Q2 2014 financial results after the market close on Tuesday, August 12, 2014.

CytoSorbents enters into distribution agreement for CytoSorb in Taiwan
M2 - Wed Aug 06, 6:33AM CDT
Immunotherapy company CytoSorbents (OTC BB:CTSO) said on Tuesday that it has signed a distribution agreement for its CytoSorb extracorporeal cytokine adsorber in Taiwan.

CytoSorbents Expands Distribution to Taiwan with Hemoscien Corporation
PR Newswire - Tue Aug 05, 5:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses, announced distribution of its CytoSorb® extracorporeal cytokine adsorber in Taiwan through an exclusive agreement with Hemoscien Corporation. This multi-year agreement is subject to annual minimum guaranteed orders of CytoSorb® to maintain exclusivity.

First Publication Using CytoSorb® Therapy During Cardiac Surgery
PR Newswire - Thu Jul 17, 5:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber in multiple countries worldwide, announced the PDF availability of the first publication describing the use of CytoSorb® intra-operatively during cardiac surgery at the Ludwig Maximilian University of Munich Hospital - Grosshadern Campus, in Germany.

CytoSorbents Consolidates SEC and International Legal Counsel with DLA Piper
PR Newswire - Wed Jul 09, 7:30AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses, announced consolidation of its SEC and international legal counsel with the global law firm, DLA Piper LLP. DLA Piper is one of the largest international business law firms with offices in major markets around the world and legal expertise across a broad range of areas including corporate and finance, litigation and arbitration, Sarbanes Oxley compliance, government affairs, labor law, intellectual property and technology, and tax.

Eagle Pharmaceuticals (EGRX) in Focus: Stock Moves 5.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:21AM CDT
Eagle Pharmaceuticals Inc. (EGRX) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.

Merriman Capital Initiates Research Coverage on CytoSorbents Corporation
Thomson Reuters ONE - Thu Jun 19, 8:33AM CDT
SAN FRANCISCO - June 19, 2014 - Merriman Capital, Inc. ("Merriman" , a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced that it has initiated equity research coverage of CytoSorbents Corporation (OTCQB: CTSO) with a Buy rating.

Cardica Inc. (CRDC) Soars: Stock Adds 10.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 8:21AM CDT
Cardica Inc. (CRDC) was a big mover last session, as the company saw its shares rise by over 10% on the day.

Oracle Hits New Yearly High; Cytosorbents Posts Record Q4 in 2013
ACCESSWIRE - Tue Apr 01, 12:57AM CDT
Oracle Corporation (NYSE: ORCL) - For an in-depth report on Oracle Corporation follow: www.BullTrends.com/stockquote/ORCL

CytoSorbents Posts Record Q4 2013 and Full Year 2013 Revenue
PR Newswire - Mon Mar 31, 3:05PM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit, provides an operational summary and financial results for the fiscal year ending December 31, 2013.

CytoSorbents to Report Fiscal 2013 Operating and Financial Results
PR Newswire - Tue Mar 25, 6:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood filter to treat life-threatening illnesses in the intensive care unit, will report fiscal 2013 financial results after the market close on Monday, March 31, 2014.

CytoSorbents to Sponsor CytoSorb® Research Symposium at ISICEM 2014
PR Newswire - Thu Mar 13, 5:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit, announced that it will sponsor a research symposium entitled:

CytoSorbents Corporation Announces $10,200,000 Registered Direct Offering
PR Newswire - Fri Mar 07, 8:31AM CST
CytoSorbents Corporation (OTCBB: CTSO), a Nevada corporation, today announced that it has entered into subscription agreements with certain institutional investors to sell approximately $10,200,000 of its common stock and warrants to purchase common stock in a registered direct offering.

Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Mar 07, 8:00AM CST
Vista Partners ("Vista" announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of March. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.

National Institutes of Health Grant Urges Latino Males to Receive Free Confidential HIV Testing
PR Newswire - Wed Jan 29, 7:30AM CST
Today marks the launch of "Conoces a Pepe? Have you met Pepe?," a social impact campaign focusing on educating and mobilizing Hispanic/Latino communities to live their best life with HIV testing and taking responsibility for their health.

Stryker Hits 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 9:20AM CST
Shares of Stryker Corporation were favorably affected by its announcement of acquiring Irvine, Calif.-based Patient Safety Technologies